

GLAXOSMITHKLINE PLC  
Form 6-K  
February 24, 2009

**FORM 6-K**

**SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549**

**Report of Foreign Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934**

For period ending February 2009

**GlaxoSmithKline plc**  
(Name of registrant)

**980 Great West Road, Brentford, Middlesex, TW8 9GS**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934.

Yes No x

--

**Notification of Transactions of Directors and  
Persons Discharging Managerial Responsibility**

I give below details of changes in the interests of:

- Persons Discharging Managerial Responsibility in the Ordinary shares of GlaxoSmithKline plc in respect of the under mentioned persons arising from the sale of Ordinary shares at a price of £11.33 per Ordinary share on 23 February 2009 to meet their tax liabilities following the vesting of a Share Value Plan award:

	<b>No. of Shares Awarded</b>	<b>No. of Shares Sold</b>	<b>No. of Shares Retained</b>
Mr S M Bicknell	3,160	1,296	1,864
Mr E J Gray	3,350	1,374	1,976
Mr D Learmouth	3,160	1,296	1,864
Mr D S Redfern	3,350	1,374	1,976
Ms C Thomas	2,520	1,034	1,486

- Persons Discharging Managerial Responsibility in the American Depositary Shares (ADSs) of GlaxoSmithKline plc in respect of the under mentioned person arising from the sale of ADSs at a price of \$32.55 per ADS on 23 February 2009 to meet his tax liabilities following the vesting of a Share Value Plan award:

	<b>No. of ADSs Awarded</b>	<b>No. of ADSs Sold</b>	<b>No. of ADSs Retained</b>
Mr W C	1,480	496	984

Louv

The Company and Persons Discharging Managerial Responsibility were advised of these transactions on 24 February 2009.

This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

V A Whyte  
Deputy Company Secretary

24 February 2009

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

**GlaxoSmithKline plc**  
(Registrant)

Date: February 24 2009

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc